title: Transcription-mediated chimeric RNAs in prostate cancer: time to revisit old hypothesis?
abstract: Chromosomal rearrangements and fusion genes play important roles in tumor development and progression. Four high-frequency prostate cancer-specific fusion genes were recently reported in Chinese cases. We attempted to confirm one of the fusion genes, USP9Y-TTTY15, by reverse transcription PCR, but detected the presence of the USP9Y-TTTY15 fusion transcript in cancer samples, nonmalignant prostate tissues, and normal tissues from other organs, demonstrating that it is a transcription-induced chimeric RNA, which is commonly produced in normal tissues. In 105 prostate cancer samples and case-matched adjacent nonmalignant tissues, we determined the expression level of USP9Y-TTTY15 and a previously reported transcription-induced chimeric RNA, SLC45A3-ELK4. The expression levels of both chimeric RNAs vary greatly in cancer and normal cells. USP9Y-TTTY15 expression is neither higher in cancer than adjacent normal tissues, nor correlated with features of advanced prostate cancer. Although the expression level of SLC45A3-ELK4 is higher in cancer than normal cells, and a dramatic increase in its expression from normal to cancer cells is correlated with advanced disease, its expression level in cancer samples alone is not correlated with any clinical parameters. These data show that both chimeric RNAs contribute less to prostate carcinogenesis than previously reported.
authors.affiliation: 1 Department of Pathology, The First Affiliated Hospital, Zhejiang University Medical College , Hangzhou, China .
authors.forename: Guoping
authors.initials: G
authors.lastname: Ren
authors.forename: Yanling
authors.initials: Y
authors.lastname: Zhang
authors.forename: Xueying
authors.initials: X
authors.lastname: Mao
authors.forename: Xiaoyan
authors.initials: X
authors.lastname: Liu
authors.forename: Emma
authors.initials: E
authors.lastname: Mercer
authors.forename: Jacek
authors.initials: J
authors.lastname: Marzec
authors.forename: Dong
authors.initials: D
authors.lastname: Ding
authors.forename: Yurong
authors.initials: Y
authors.lastname: Jiao
authors.forename: Qingchong
authors.initials: Q
authors.lastname: Qiu
authors.forename: Yue
authors.initials: Y
authors.lastname: Sun
authors.forename: Biao
authors.initials: B
authors.lastname: Zhang
authors.forename: Marc
authors.initials: M
authors.lastname: Yeste-Velasco
authors.forename: Claude
authors.initials: C
authors.lastname: Chelala
authors.forename: Daniel
authors.initials: D
authors.lastname: Berney
authors.forename: Yong-Jie
authors.initials: YJ
authors.lastname: Lu
mesh_terms: D000368:Aged; D006801:Humans; D008297:Male; D026901:Membrane Transport Proteins / Q000235:genetics / Q000378:metabolism; D015778:Minor Histocompatibility Antigens; D009004:Monosaccharide Transport Proteins; D009367:Neoplasm Staging; D015514:Oncogene Proteins, Fusion / Q000235:genetics* / Q000378:metabolism; D011467:Prostate / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D022661:RNA, Untranslated / Q000235:genetics* / Q000378:metabolism; D014158:Transcription, Genetic; D059467:Transcriptome; D043222:Ubiquitin Thiolesterase / Q000235:genetics / Q000378:metabolism; D050808:ets-Domain Protein Elk-4 / Q000235:genetics / Q000378:metabolism
chemical_list: C494193:ELK4 protein, human; D026901:Membrane Transport Proteins; D015778:Minor Histocompatibility Antigens; D009004:Monosaccharide Transport Proteins; D015514:Oncogene Proteins, Fusion; D022661:RNA, Untranslated; C551031:SLC45a3 protein, human; C481724:USP9Y protein, human; D050808:ets-Domain Protein Elk-4; D043222:Ubiquitin Thiolesterase